Bioengineered cells-derived vesicles as drug-delivery carriers for targeted cancer therapy소포 유래 생체공학 세포를 이용한 표적지향 항암치료용 약물전달체 개발

Cited 0 time in webofscience Cited 0 time in scopus
  • Hit : 792
  • Download : 0
Advances in genetic engineering tools have contributed to the development of strategies for utiliz-ing biologically derived vesicles as nanomedicines for achieving cell-specific drug delivery. Substantial efforts has been undertaken to understand the key attributes of natural drug carriers, such as physicochem-ical properties, drug loading efficiency, cancer targeting ability, cell entry mechanism, antigenic compo-nents and immunogenic potentials. Importantly, such engineered vesicles are utilized for delivery of vari-ous therapeutic payloads including small interfering RNA (siRNA) and chemotherapeutic agents. Here, I describe the natural drug delivery carriers derived from bioengineered bacteria or yeast cells, and demon-strated their utility in treating cancer. In chapter 2, I described bacterially derived nano-sized outer membrane vesicles (OMVs) as an ideal vector for encapsulation of therapeutic siRNA and cell specific delivery. I prepared OMVs from a bacterial strain, genetically engineered to have intrinsically low endotoxicity and over express cancer cell receptor specific high affinity protein (Affibody) on surface. Such engineered bio-vesicles were loaded with kinesin spindle protein (KSP) siRNA by employing simple electroporation protocol. The siRNA kinet-ics study assured receptor mediated OMV endocytosis, intracellular degradation and release of siRNA at therapeutically significant concentration. Consequently, significant inhibition of cell proliferation was ob-served. The OMVs I developed had reduced endotoxicity and immunogenicity to human cells. More im-portantly, due to their biological origin these nanoparticles are biodegradable and production scale up is easy. In chapter 3, I described yeast derived vacuoles as an ideal vector for chemotherapeutic agents. I prepared vacuoles from yeast strain which is genetically engineered to express cancer targeting ligand -affibody, on the surface of vacuoles. A simple mixing protocol was developed for...
Advisors
Jon, Sang-Yongresearcher전상용
Description
한국과학기술원 : 생명과학과,
Publisher
한국과학기술원
Issue Date
2014
Identifier
591767/325007  / 020122508
Language
eng
Description

학위논문(박사) - 한국과학기술원 : 생명과학과, 2014.8, [ xii, 153 p ]

Keywords

affibody; siRNA; 약물전달; 항암제; 암 치료; 생물학적 유래 전달체; bioengineered cells; biological vesicles; cancer therapy; chemotherapeutic agents; drug delivery; siRNA; 어피바디; 바이오엔지니어링

URI
http://hdl.handle.net/10203/196240
Link
http://library.kaist.ac.kr/search/detail/view.do?bibCtrlNo=591767&flag=dissertation
Appears in Collection
BS-Theses_Ph.D.(박사논문)
Files in This Item
There are no files associated with this item.

qr_code

  • mendeley

    citeulike


rss_1.0 rss_2.0 atom_1.0